In April, the value of biopharma deals climbed to $15.28 billion, increasing 84% from March’s $8.29 billion and also up from February’s $7.76 billion, though there was a decline from January’s $27.9 billion. This amounts to a monthly average of $14.86 billion in deal value for 2024, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As dipped to $1.33 billion for the month, marking the lowest figure in nearly a year.

As South Korea’s Curocell Inc. looks to develop the country’s first homegrown CAR T-cell therapy, CEO Gunsoo Kim highlighted rising and falling trends in the global CAR T development space at Bio Korea 2024.

Med-tech deal value increased in April, reaching $172.37 million, a 538% bump from March’s $27 million. However, the monthly average for deal value in 2024 stands at $140.68 million, reflecting an 84% decline from the 2023 monthly average of $886.13 million.

The BioWorld Infectious Disease Index (BIDI) has continued to decline in the first four months of 2024, finishing April with a year-to-date decrease of 25.12%. BIDI trailed both the Nasdaq Biotechnology Index, which saw a 4.76% downturn by April’s end, and the Dow Jones Industrial Average, which closed the month with a 0.34% increase for the year. In 2023, BIDI ended the year with a 43.48% decline, preceded by an 83.57% drop in 2022.

In April, the value of biopharma deals climbed to $15.28 billion, increasing 84% from March’s $8.29 billion and also up from February’s $7.76 billion, though there was a decline from January’s $27.9 billion. This amounts to a monthly average of $14.86 billion in deal value for 2024, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As dipped to $1.33 billion for the month, marking the lowest figure in nearly a year.

Homerun success of Novo Nordisk A/S’ semaglutide, which recently became the U.S.’s biggest blockbuster drug, is serving as an “inflection point” for obesity therapeutics and fueling the drive for new and improved therapies, speakers said at Bio Korea 2024 on May 8.

Although the $6.03 billion in biopharma financings raised in April is down from $13.84 billion in financings in March and $22.3 billion in February, the monthly average of $13.29 billion for all financings is up 125% from the average of $5.91 billion a month in 2023.